HTDS - Hard to Treat Diseases (PINK)

[sterling]

I have played the ups and downs on HTDS and am mostly out now as I suspected these pullbacks. I'm keeping a close watch on it to see how it rolls the next few days and weeks - will it continue to have strong support at the .004 mark? Will it keep seeing lower lows and lower highs?
The rally that we saw this week, IMO, was a bit ahead of itself (I've been watching it for almost 2 months). It was an awesome run-up, but I hope people don't see it as a complete pump and dump. There will be more in store in September and down the road this year. So I want to get more at major dips, question is, are the dips going to be at .004, in the .003's or .002s or even back to where it was for many weeks at around .001. Don't know.

[robo]

I am on board w/ HTDS.... not sure how it will play out... what are your thoughts??? It seems to be staying steady around .004

Despite the long term potential of HTDS, this stock had a pronounced upward surge the prior 2 days and there will likely be further profit-taking, imo.

There is a large gap on the chart to fill down to .0025.
That might be an area to grab shares for a longer hold or potential bounce.

glta

[nj1869]

Did anyone buy HTDS. I'm in with 300k at .003. Investment report from google.

August 2, 2009
Hard to Treat Diseases Inc. (OTCPK: HTDS)


Hard to Treat Diseases Inc. (HTDS) is an emerging company focused on
the development and licensing of proprietary technologies. HTDS
acquired China-based Shenzhen Mellow Hope Pharm Industrial Co. Ltd,
the biggest exporter of biological vaccines in China. It also has
controlling interest in Slavica BioChem, a Serbian company whose
primary focus involves the enhancement and modification of existing
approved drugs such as “Virazole” for the purpose of chemical repair
of damage to the CNS (central nervous system), MS (Multiple
Sclerosis), SARS, Hepatitis C and HIV.


HTDS is a Florida corporation and was incorporated in 1993.


Financial Summary


In an unaudited quarterly report for the period ended Mary 31, 2009,
HTDS reported sales of $1,306,680. Total cost of sales came in at
$1,125,636, bringing gross profit to $181,044.


HTDS posted Cash Flows from operating activities of -$35,964 while it
used $101,012 for financing activities, and -$143,364 in investing
activities. Cash at end of period totaled $188,652.


The Company mentioned in the report that it has adopted a policy
regarding the payment of dividends. It stated that dividends may be
paid to shareholders once all divisions are fully operational and
profitable. In addition, the board may pay dividends to counter any
short selling or undermining of the entity.


On February 20, 2009, the Company announced it has closed the merger
agreement with Shenzhen Mellow Hope Pharm Industrial Co. (Mellow
Hope). It was previously reported that Mellow Hope revenues are
currently in excess of $15 million, and growing. Based on a stock
certificate signed March 26, 2009, Mellow Hope acquisition has been
completed for 3.5 billion shares.


Analyst Consensus


There are currently no analysis and research available at this stage
of Company’s development.


Investment Highlights


HTDS’ strategy to increase shareholder value, separate from the
operating performance of operating subsidiaries, is by spinning off
and distributing shares of its wholly owned subsidiaries in the form
of a special dividend to the Company’s shareholders.


HTDS secured a niche in the fast-emerging global vaccine market
following the acquisition of Mellow Hope in February. Mellow Hope’s
current revenues are reportedly in excess of $15 million, and growing.
As the biggest exporter of biological vaccines in the China, Mellow
Hope has a product line that encompasses vaccines for influenza,
tetanus, diphtheria and other diseases; blood-based products including
human rabies immunoglobulin; and active pharmaceutical ingredients (or
APIs) for injection such as celestatin.


Mellow Hope’s agreement with Yunnan Walvax Biotech Co. Ltd, the second
biggest manufacturer of Haemophilus influenza type b conjugate vaccine
in China, further boosted its valuation. As per agreement with Yunnan
Walvax Biotech Co., Mellow Hope will be fully authorized to do the
international marketing of Haemophilus influenza type “B” conjugate
vaccine in the global market. The agreement could provide an enormous
benefit to the Company if they recover 100% intellectual property (IP)
rights.


The global vaccine market is seen as one of the most lucrative segment
in the global pharmaceutical industry. Research company RNCOS reported
that U.S. and Europe represent the two largest vaccine markets in the
world and will continue experiencing healthy growth rate in future.


HTDS’ wholly owned subsidiary Slavica BioChem focuses on the
enhancement and modification of existing approved drugs such as
“Virazole” for the purpose of chemical repair of damage to the CNS
(central nervous system), MS (Multiple Sclerosis), SARS, hepatitis C
and HIV. Other interests include an online cosmetics company.


The Company recently advanced its foothold in the MS (Multiple
Sclerosis) market, which had a total global revenues of more than $6
billion in 2008, according to market research. On July 23, HTDS
reported that researchers in its Slavica BioChem division have advised
of some significant findings regarding its research into the use of
Ribavirin in the treatment of MS. With Ribavirin as a potential
treatment, HTDS could address the need of people suffering from this
chronic, inflammatory disease that affects the central nervous. The
World Health Organization (WHO) estimates that more than 2.5 million
people suffer from MS worldwide.


The Company recently announced the appointment of Prof. Mirjana
Stojiljkovic, a well respected scientist who leads a group of
researchers from Department of Neurobiology, Institute for Biological
Research “Sinisa Stankovic” at the University of Belgrade in Serbia,
(IBISS group), as the company’s medical adviser.


Commenting on the latest developments, HTDS CEO Terry Yuan stated,
“There is great synergy between the two companies Slavica BioChem and
Mellow Hope. Although Slavica currently has no revenues, their
developmental and research contributions have the potential to
transform into enormous and massive gains for HTDS and its
shareholders.”


The Company expects to release its second-quarter financials and some
positive updates on the IP issue very shortly.


As of last close on July 30 2009, HTDS closed at 0.004, 300.00% above
the 52-week low of 0.001 set September 07, 2007.

[d1nonly]

When flu season comes and the IP returned to this company, this will fly.

[asapakeem]

I will hold onto til flu season then see what happens, cheap enough to take the risk

[bbollinger]

Anybody have any info on when the updated financials will come out? I heard they were currently being translanted into english. In any case, with the two subsidiaries now properly being audited i would expect a decent statement this quarter that will more accurately reflect the value of this company.

[unsignedballer]

Does anyone know how many shares outstandings HTDS has?

[DogDayTrader]

According to ScotTrade, 5.0 Billion.

[archi]

HTDS is definitely a great play near-term and through the flu season. Next week they release earnings which will probably detail the Intellectual Property rights re-claimed and decent earnings ahead of the flu season. There was a PR today re: Flu vaccine doses supplied to Chile, 2-5million...this is a massive increase from their usual supplies to individual countries of 250-500k...

I saw a valuation on the Google HTDS m/b (very active and full of large investors) which stated 5 billion shares o/s;

"HTDS at 0.001 is way undervalue.. Here is the sum
let’s presume that the HTDS Outstanding Shares
(OS) amount is maxed out to be what their AS is (5 Billion Shares) to
derive a valuation.
Let’s figure a conservative 25% Net Profit Margin from the over $15
million in Revenues that is generated by their subsidiary, Mellow
Hope.
Now consider the derived Earnings Per Share (EPS) below:
OS = 5,000,000,000 Shares
Net Income = 25% x $15,000,000 = $3,750,000
Net Income ÷ OS = EPS
$3,750,000 ÷ 5,000,000,000 OS Shares = EPS .00075 = EPS
PE Ratio x EPS = Fundamental Share Price Valuation
12 Conservative PE Ratio x .00075 = Fundamental Share Price Valuation
.009 per share = Fundamental Share Price Valuation"

I believe this is very understated given 1) Intellectual propery re-claim of over $15million 2) Expanded Flu season revenues and 3) MS and other pipeline capabilities

JMHO

[sterling]

Archi, I just read this one the google board, posted by Brien Lee, gives an interesting estimate of pps based on cost of vaccine, higher than what you have. Quoted below:

"
www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm

From the latest PR news, it seems that the vaccine HTDS is selling to
Chile will be the Polysaccharide Vaccine, which I am not too familiar
with. But either way, I've been trying to do a bit of calculation for
how this will affect the value of HTDS as a company. The vaccine can
be anywhere around $10-$30, and the amount of sales is anywhere around
2-5 million.
So let's find out what we can expect at the least, and at the most.
Least we can expect:
$10 * 2,000,000 = $20,000,000 in revenues.
A conservative 25% profit margin will give us $5,000,000 in profit.
$5,000,000 / 5,000,000,000 outstanding shares = 0.001 Earning per
share.
0.001 EPS * conservative 12 P/E ratio = 0.012 PPS (which does not
include any other news)
Most we can expect:
$30 * 5,000,000 = $150,000,000 in revenues.
A conservative 25% profit margin will give us $37,500,000 in profit.
$37,500,000 / 5,000,000,000 outstanding shares = 0.0075 Earning per
share.
0.0075 * conservative 12 P/E ratio = 0.09 PPS (not including any other
news)
So in short, based on the above calculations, we can value HTDS at
anywhere between 0.012 and 0.09 merely based on this positive news. Of
course, given the IP rights and positive Q2 financials, we can slide
our expectations more to the right side, not to mention all the other
orders we are getting from various continents. However, the 25% profit
margin is just a guesstimate number. It could be more, it could be
less. But either way, it is nice to see in actual numbers where HTDS
is headed. "